Ahmad Taufik S
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ahmad Taufik S has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Adnanto Wiweko
Faculty of Medicine Mataram University, Indonesia; Stem Cell and Regenerative Medicine Center, Mataram University Teaching Hospital, Indonesia
3 shared publicationsMohammad Rizki
Faculty of Medicine Mataram University, Indonesia; Stem Cell and Regenerative Medicine Center, Mataram University Teaching Hospital, Indonesia
3 shared publicationsBayu Tirta Dirja
Faculty of Medicine Mataram University, Indonesia; Stem Cell and Regenerative Medicine Center, Mataram University Teaching Hospital, Indonesia
2 shared publicationsDidit Yudhanto
Faculty of Medicine Mataram University, Indonesia; Stem Cell and Regenerative Medicine Center, Mataram University Teaching Hospital, Indonesia; Doctorate Program, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
2 shared publications- Bayu Tirta Dirja
Faculty of Medicine, Universitas Mataram, Lombok, Indonesia
1 shared publication Budu
1 shared publication
Latest Publications
- Open Access
- 29 June 2022
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 97 (C) , 107370
Treatment of bone defects with bovine hydroxyapatite xenograft and platelet rich fibrin (PRF) to accelerate bone healing
Introduction: The autograft treatment has become a gold standard therapy for bone defects, although it has its drawbacks and a side effect of donor site morbidity. Furthermore, the bovine hydroxyapatite xenograft due to its excellent osteoconduction characteristic combined with platelet-rich fibrin (PRF), which is a source of growth factor, makes both utilized as therapeutic measures. Therefore, this study examines the potential use of bovine hydroxyapatite xenograft and platelet-rich fibrin in the treatment of bone defects. Method: The report on three cases of bone defects that were treated using a combination of bovine hydroxyapatite xenograft and platelet-rich fibrin (PRF) for internal fixation and grafting was used for this investigation. The study showed that delayed and non-union fractures of the femur, humerus, and tibia may cause bone deformities. Result: The outcome revealed a positive clinical and radiological finding about using the combination of bovine hydroxyapatite xenograft and platelet-rich fibrin (PRF) in the repair of bone defects and acceleration of healing processes. Conclusion: The use of a combination of bovine hydroxyapatite xenograft and platelet-rich fibrin (PRF) in the repair of bone defects shows more effective and accelerated healing. Future studies with a bigger sample size may be carried out and are expected to yield optimal results. Highlights:
- 29 June 2022
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 97 (C) , 107370
Open AccessTreatment of bone defects with bovine hydroxyapatite xenograft and platelet rich fibrin (PRF) to accelerate bone healing
Introduction: The autograft treatment has become a gold standard therapy for bone defects, although it has its drawbacks and a side effect of donor site morbidity. Furthermore, the bovine hydroxyapatite xenograft due to its excellent osteoconduction characteristic combined with platelet-rich fibrin (PRF), which is a source of growth factor, makes both utilized as therapeutic measures. Therefore, this study examines the potential use of bovine hydroxyapatite xenograft and platelet-rich fibrin in the treatment of bone defects. Method: The report on three cases of bone defects that were treated using a combination of bovine hydroxyapatite xenograft and platelet-rich fibrin (PRF) for internal fixation and grafting was used for this investigation. The study showed that delayed and non-union fractures of the femur, humerus, and tibia may cause bone deformities. Result: The outcome revealed a positive clinical and radiological finding about using the combination of bovine hydroxyapatite xenograft and platelet-rich fibrin (PRF) in the repair of bone defects and acceleration of healing processes. Conclusion: The use of a combination of bovine hydroxyapatite xenograft and platelet-rich fibrin (PRF) in the repair of bone defects shows more effective and accelerated healing. Future studies with a bigger sample size may be carried out and are expected to yield optimal results. Highlights:
- 1 January 2021
- Published by Atlantis Press SARL
- p. 331-335
Cell Multiplication in Platelet Rich Fibrin (PRF) and Platelet Rich Plasma (PRP) as Biofuels for Cartilage Tissue Engineering
- 1 January 2021
- Published by Atlantis Press SARL
- p. 331-335
Cell Multiplication in Platelet Rich Fibrin (PRF) and Platelet Rich Plasma (PRP) as Biofuels for Cartilage Tissue Engineering
- Open Access
- 22 September 2015
- Published by Springer Nature in Malaria Journal
- Vol. 14 (1) , 365
Distribution of Plasmodium vivax pvdhfr and pvdhps alleles and their association with sulfadoxine–pyrimethamine treatment outcomes in Indonesia
Sympatric existence of Plasmodium falciparum and Plasmodium vivax, and the practice of malaria treatment without microscopic confirmation suggest that the accidental treatment of vivax malaria with sulfadoxine–pyrimethamine (SP) is common. In this study, the frequency distribution of alleles associated with SP resistance were analysed among the P. vivax infections from malariometric surveys and its association with SP treatment failure in clinical studies in Indonesia. The dhfr and dhps alleles were detected using PCR–RFLP method. Analysis of 159 P. vivax isolates from malariometric surveys and 69 samples from in vivo SP efficacy study revealed various the existence of various alleles of the pvdhfr and pfdhps genes including 57L/I, 58R, 61M, and 117N/T. Allele 13L of the dhfr gene and 553G of the dhps gene were not detected in any isolates examined in both studies. In the dhfr gene, tandem repeat type-A was the major tandem repeat observed in any isolates analysed. In the dhps gene, only the 383G allele was observed. Isolates carrying double, triple and quadruple mutants of dhfr gene were found in Lampung, Purworejo, Sumba, and Papua. Although this study revealed a wide distribution of dhfr and dhps alleles among the P. vivax isolates across a broad geographic regions in Indonesia, impact on SP efficacy was not observed in Sumba. With proper malaria diagnosis, SP may still be used as a rational anti-malarial drug either as a single prescription or in combination with artemisinin.
- 22 September 2015
- Published by Springer Nature in Malaria Journal
- Vol. 14 (1) , 365
Open AccessDistribution of Plasmodium vivax pvdhfr and pvdhps alleles and their association with sulfadoxine–pyrimethamine treatment outcomes in Indonesia
Sympatric existence of Plasmodium falciparum and Plasmodium vivax, and the practice of malaria treatment without microscopic confirmation suggest that the accidental treatment of vivax malaria with sulfadoxine–pyrimethamine (SP) is common. In this study, the frequency distribution of alleles associated with SP resistance were analysed among the P. vivax infections from malariometric surveys and its association with SP treatment failure in clinical studies in Indonesia. The dhfr and dhps alleles were detected using PCR–RFLP method. Analysis of 159 P. vivax isolates from malariometric surveys and 69 samples from in vivo SP efficacy study revealed various the existence of various alleles of the pvdhfr and pfdhps genes including 57L/I, 58R, 61M, and 117N/T. Allele 13L of the dhfr gene and 553G of the dhps gene were not detected in any isolates examined in both studies. In the dhfr gene, tandem repeat type-A was the major tandem repeat observed in any isolates analysed. In the dhps gene, only the 383G allele was observed. Isolates carrying double, triple and quadruple mutants of dhfr gene were found in Lampung, Purworejo, Sumba, and Papua. Although this study revealed a wide distribution of dhfr and dhps alleles among the P. vivax isolates across a broad geographic regions in Indonesia, impact on SP efficacy was not observed in Sumba. With proper malaria diagnosis, SP may still be used as a rational anti-malarial drug either as a single prescription or in combination with artemisinin.